INTRODUCTION: Retroperitoneal sarcoma is a surgically managed condition that can recur locally following macroscopically complete resection. Owing to the low incidence of the condition, advances in treatment are reported infrequently but complete compartmental resection and adjuvant or neoadjuvant radiotherapy are areas under investigation. Given the practical difficulty of randomised trials, observational data can highlight advantages from progressive treatment approaches. METHODS: A retrospective database of consecutive retroperitoneal sarcoma resections performed at a single referral centre between March 1997 and March 2013 was interrogated. Histological, radiological and clinical data were collected. Univariate and multivariate analyses for disease free and overall survival were performed to establish independent predictors of disease recurrence and patient survival. RESULTS: A total of 79 patients underwent 90 resections (63 primary). The mean five-year overall and disease free survival rates were 55.3% and 24.8% respectively. Higher patient age, high tumour grade, presence of extraretroperitoneal disease and invasive tumour phenotype were found to significantly predict survival following multivariate analysis. Half (50%) of the tumours displayed invasive behaviour on histopathology and 42% of locoregional recurrence was intraperitoneal. CONCLUSIONS: Retroperitoneal sarcoma is commonly an infiltrative tumour and often recurs outside of the retroperitoneum. These features limit the therapeutic impact of interventions that focus on gaining local control such as complete compartmental resection and radiotherapy. It seems likely that future advances in the management of this cancer will involve new systemic agents to treat this frequently systemic disease.
INTRODUCTION:Retroperitoneal sarcoma is a surgically managed condition that can recur locally following macroscopically complete resection. Owing to the low incidence of the condition, advances in treatment are reported infrequently but complete compartmental resection and adjuvant or neoadjuvant radiotherapy are areas under investigation. Given the practical difficulty of randomised trials, observational data can highlight advantages from progressive treatment approaches. METHODS: A retrospective database of consecutive retroperitoneal sarcoma resections performed at a single referral centre between March 1997 and March 2013 was interrogated. Histological, radiological and clinical data were collected. Univariate and multivariate analyses for disease free and overall survival were performed to establish independent predictors of disease recurrence and patient survival. RESULTS: A total of 79 patients underwent 90 resections (63 primary). The mean five-year overall and disease free survival rates were 55.3% and 24.8% respectively. Higher patient age, high tumour grade, presence of extraretroperitoneal disease and invasive tumour phenotype were found to significantly predict survival following multivariate analysis. Half (50%) of the tumours displayed invasive behaviour on histopathology and 42% of locoregional recurrence was intraperitoneal. CONCLUSIONS:Retroperitoneal sarcoma is commonly an infiltrative tumour and often recurs outside of the retroperitoneum. These features limit the therapeutic impact of interventions that focus on gaining local control such as complete compartmental resection and radiotherapy. It seems likely that future advances in the management of this cancer will involve new systemic agents to treat this frequently systemic disease.
Authors: M Toulmonde; S Bonvalot; P Méeus; E Stoeckle; O Riou; N Isambert; E Bompas; M Jafari; C Delcambre-Lair; E Saada; A Le Cesne; C Le Péchoux; J Y Blay; S Piperno-Neumann; C Chevreau; J O Bay; V Brouste; P Terrier; D Ranchère-Vince; A Neuville; A Italiano Journal: Ann Oncol Date: 2014-03 Impact factor: 32.976
Authors: Chee-Chee H Stucky; Nabil Wasif; Jonathan B Ashman; Barbara A Pockaj; Leonard L Gunderson; Richard J Gray Journal: J Surg Oncol Date: 2014-02-21 Impact factor: 3.454
Authors: A Gronchi; R Miceli; C Colombo; S Stacchiotti; P Collini; L Mariani; C Sangalli; S Radaelli; R Sanfilippo; M Fiore; P G Casali Journal: Ann Oncol Date: 2011-07-16 Impact factor: 32.976
Authors: Sylvie Bonvalot; Rosalba Miceli; Mattia Berselli; Sylvain Causeret; Chiara Colombo; Luigi Mariani; Hatem Bouzaiene; Cécile Le Péchoux; Paolo Giovanni Casali; Axel Le Cesne; Marco Fiore; Alessandro Gronchi Journal: Ann Surg Oncol Date: 2010-06 Impact factor: 5.344
Authors: Isabelle Ray-Coquard; Jean-Yves Blay; Antoine Italiano; Axel Le Cesne; Nicolas Penel; Jianguo Zhi; Florian Heil; Ruediger Rueger; Bradford Graves; Meichun Ding; David Geho; Steven A Middleton; Lyubomir T Vassilev; Gwen L Nichols; Binh Nguyen Bui Journal: Lancet Oncol Date: 2012-10-17 Impact factor: 41.316
Authors: William W Tseng; John E Madewell; Wei Wei; Neeta Somaiah; Alexander J Lazar; Markus P Ghadimi; Aviad Hoffman; Peter W T Pisters; Dina C Lev; Raphael E Pollock Journal: Ann Surg Oncol Date: 2014-04-07 Impact factor: 5.344
Authors: Antonio Chiappa; Emilio Bertani; Gabriella Pravettoni; Andrew Paul Zbar; Diego Foschi; Giuseppe Spinoglio; Bernardo Bonanni; Gianluca Polvani; Federico Ambrogi; Maria Laura Cossu; Carlo Ferrari; Marco Venturino; Cristiano Crosta; Luca Bocciolone; Roberto Biffi Journal: Indian J Surg Date: 2018-01-31 Impact factor: 0.656